CHICAGO and PHOENIX, Jan. 9 /PRNewswire/ -- Houlihan Smith & Co., Inc. acted as the exclusive advisor in arranging a non-control equity investment into Sottera, Inc. d/b/a NJOY, as announced by Charles Botchway, Group Managing Director and Vice Chairman of Houlihan Smith & Company, Inc. The transaction was led by Houlihan Smith Managing Director Reginald McGaugh. Terms were not disclosed.
"We appreciate the process management and financial advisory services provided by Reginald McGaugh and his team at Houlihan Smith & Company, Inc. related to this equity investment," said Jack Leadbeater, CEO of Sottera. "We look forward to continuing our capital-raising process with Mr. McGaugh and his team as we continue our international growth."
"This investment represents a significant opportunity for NJOY to achieve growth initiatives related to its revolutionary product," said McGaugh, who worked directly with NJOY to establish the equity investment. "The facility will be used to support the continued growth of NJOY based on recently signed distribution agreements in North America, South America, and Asia."
Based in Scottsdale, Arizona, Sottera has filed for patents to manufacture and distribute groundbreaking products and technology represented by the trademarked brand NJOY (http://www.njoy.com). The name Sottera is derived from Soteria, the Greek god of preservation, redemption and salvation. These three words are the essence of the NJOY brand and products, which give tobacco users the opportunity to continue smoking with greater freedom, lower cost and more social acceptance. NJOY is currently being sold in all 50 states and in more than 25 foreign countries. NJOY is available online at http://www.njoy.com for shipment around the globe, and is also available on affiliated websites and at retail locations across the U.S.
Miri Pharma, Inc. is a division of Canderm Pharma, Inc. Canderm Pharma, Inc. develops and sells cosmeceuticals, over-the-counter (OTC) skin care products, and dermatological items. Its product line includes ArtteSense, Betacaine, Cliniderm, Lipsorex, NeoStrata, Rosacure, and Ultraquin, as well as Condyline Topical Solution, Dermagran II, Epi-Derm, and UltraMOP. The firm also sells Ayria, a skin care line sold exclusively through dermatologists, and distributes Radiesse, produced by BioForm Medical, a trendy injectable filler alternative to facelifts.
Houlihan Smith & Company, Inc. ("Houlihan") is a specialized investment banking firm that provides advisory, financing, and valuation services to public and private businesses. Houlihan is a registered broker-dealer and FINRA/SIPC Member.
Houlihan understands the time sensitivity of corporate finance, and responds quickly and tenaciously to opportunities. The Houlihan approach creates corporate finance transactions in which business owners and investors mutually benefit. We have the knowledge, experience and relationships to match buyers and sellers, as well as to match the appropriate financing and capitalization structure to each unique client situation. The Houlihan name is synonymous with professional financial expertise. We provide cost-effective fairness and solvency opinions, as well as valuations for tax and financial reporting, to some of the largest NYSE/NASDAQ companies, as well as small, privately held businesses. (http://www.houlihansmith.com)
Contact: Rebecca Carriere 312.499.5903 email@example.com
|SOURCE Houlihan Smith & Co., Inc.|
Copyright©2009 PR Newswire.
All rights reserved